NASDAQ:CFRX ContraFect Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ContraFect Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.13 -0.11 (-2.10 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$5.05Now: $5.13▼$5.2850-Day Range$5.05MA: $5.40▼$5.9252-Week Range$2.80Now: $5.13▼$13.40Volume137,234 shsAverage Volume282,568 shsMarket Capitalization$142.66 millionP/E RatioN/ADividend YieldN/ABeta1.03 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingContraFect has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, ContraFect has a forecasted upside of 211.9% from its current price of $5.13.Amount of Analyst CoverageContraFect has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesContraFect has received 221 “outperform” votes. (Add your “outperform” vote.)Underperform VotesContraFect has received 200 “underperform” votes. (Add your “underperform” vote.)Community SentimentContraFect has received 52.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote “Outperform” if you believe CFRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldContraFect does not currently pay a dividend.Dividend GrowthContraFect does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ContraFect insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of ContraFect is held by insiders.Percentage Held by Institutions55.31% of the stock of ContraFect is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ContraFect are expected to decrease in the coming year, from ($1.36) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ContraFect is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ContraFect is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContraFect has a P/B Ratio of 5.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX Previous Symbol CUSIPN/A CIK1478069 Webwww.contrafect.com Phone914-207-2300Debt Debt-to-Equity RatioN/A Current Ratio7.63 Quick Ratio7.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.58 per share Price / Cash Flow8.78 Book Value$1.01 per share Price / Book5.08Profitability EPS (Most Recent Fiscal Year)$1.11 Net Income$-12,790,000.00 Net MarginsN/A Return on Equity-133.30% Return on Assets-38.78%Miscellaneous Employees20 Outstanding Shares27,809,000Market Cap$142.66 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $5.13 -0.11 (-2.10 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CFRX News and Ratings via Email Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter. ContraFect (NASDAQ:CFRX) Frequently Asked Questions How has ContraFect's stock been impacted by COVID-19 (Coronavirus)? ContraFect's stock was trading at $6.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CFRX shares have decreased by 26.3% and is now trading at $5.13. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of ContraFect? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ContraFect. When is ContraFect's next earnings date? ContraFect is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for ContraFect. How were ContraFect's earnings last quarter? ContraFect Corp (NASDAQ:CFRX) issued its earnings results on Friday, August, 14th. The biotechnology company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.14. View ContraFect's earnings history. When did ContraFect's stock split? How did ContraFect's stock split work? ContraFect's stock reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for CFRX? 4 brokers have issued 1 year target prices for ContraFect's shares. Their forecasts range from $12.00 to $22.00. On average, they expect ContraFect's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 211.9% from the stock's current price. View analysts' price targets for ContraFect. Who are some of ContraFect's key competitors? Some companies that are related to ContraFect include Eagle Pharmaceuticals (EGRX), Zafgen (ZFGN), Legend Biotech (CALT), Omeros (OMER), XBiotech (XBIT), Syndax Pharmaceuticals (SNDX), Axovant Sciences (AXON), Geron (GERN), Flexion Therapeutics (FLXN), ZIOPHARM Oncology (ZIOP), Vanda Pharmaceuticals (VNDA), Forte Biosciences (FBRX), Radius Health (RDUS), Molecular Templates (MTEM) and Clovis Oncology (CLVS). View all competitors. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX) and Tonix Pharmaceuticals (TNXP). Who are ContraFect's key executives? ContraFect's management team includes the following people: Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57) What is ContraFect's stock symbol? ContraFect trades on the NASDAQ under the ticker symbol "CFRX." Who are ContraFect's major shareholders? ContraFect's stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (34.55%), BVF Inc. IL (10.44%), Portolan Capital Management LLC (2.01%), Minot Wealth Management LLC (0.58%), Nuveen Asset Management LLC (0.22%) and Bank of New York Mellon Corp (0.24%). Company insiders that own ContraFect stock include Cary Sucoff, Fosun Pharmaceutical Shanghai and Michael Messinger. View institutional ownership trends for ContraFect. Which major investors are buying ContraFect stock? CFRX stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BVF Inc. IL, Portolan Capital Management LLC, Nuveen Asset Management LLC, Bank of New York Mellon Corp, Worth Venture Partners LLC, Charles Schwab Investment Management Inc., and Two Sigma Advisers LP. Company insiders that have bought ContraFect stock in the last two years include Cary Sucoff, and Michael Messinger. View insider buying and selling activity for ContraFect. How do I buy shares of ContraFect? Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ContraFect's stock price today? One share of CFRX stock can currently be purchased for approximately $5.13. How big of a company is ContraFect? ContraFect has a market capitalization of $142.66 million. The biotechnology company earns $-12,790,000.00 in net income (profit) each year or $1.11 on an earnings per share basis. ContraFect employs 20 workers across the globe. What is ContraFect's official website? The official website for ContraFect is www.contrafect.com. How can I contact ContraFect? ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
